Barclays Cuts TScan Therapeutics (NASDAQ:TCRX) Price Target to $3.00

TScan Therapeutics (NASDAQ:TCRX) had its price objective lowered by stock analysts at Barclays from $14.00 to $3.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s price target indicates a potential upside of 44.23% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. Needham & Company LLC cut their price objective on shares of TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a report on Thursday. Finally, Wedbush restated an “outperform” rating and issued a $7.00 price target on shares of TScan Therapeutics in a research note on Wednesday. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $9.20.

TScan Therapeutics Stock Performance

Shares of NASDAQ TCRX opened at $2.08 on Friday. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $111.01 million, a P/E ratio of -1.96 and a beta of 0.91. TScan Therapeutics has a 12 month low of $1.82 and a 12 month high of $9.69. The stock has a 50 day moving average of $2.43 and a 200-day moving average of $4.04.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.02). The company had revenue of $0.67 million during the quarter, compared to analyst estimates of $1.43 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. As a group, equities research analysts predict that TScan Therapeutics will post -1.12 EPS for the current year.

Institutional Investors Weigh In On TScan Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Brown Brothers Harriman & Co. increased its stake in TScan Therapeutics by 88.2% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 143,051 shares of the company’s stock worth $712,000 after acquiring an additional 67,027 shares during the period. Great Point Partners LLC grew its holdings in shares of TScan Therapeutics by 8.0% during the 3rd quarter. Great Point Partners LLC now owns 1,016,375 shares of the company’s stock worth $5,062,000 after purchasing an additional 75,544 shares in the last quarter. MetLife Investment Management LLC increased its position in shares of TScan Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock worth $116,000 after purchasing an additional 13,164 shares during the period. Checkpoint Capital L.P. acquired a new position in TScan Therapeutics in the third quarter valued at about $4,110,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in TScan Therapeutics during the third quarter worth about $515,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.